AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amgen Inc (AMGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive technical indicators, and favorable analyst sentiment. Despite insider selling, the stock's fundamentals and growth potential outweigh the risks.
The stock is showing bullish momentum with MACD positively expanding at 0.605, moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200), and the price trading above the pivot level of 347.679. RSI is neutral at 48.118, suggesting no overbought or oversold conditions.
Strong financial performance in Q4 2025 with revenue up 8.58% YoY, net income up 112.60% YoY, and EPS up 112.07% YoY.
Positive analyst sentiment with multiple firms raising price targets, including UBS ($
and RBC Capital ($370), reflecting confidence in Amgen's growth potential.
Bullish technical indicators and favorable options sentiment.
Insider selling has increased significantly by 475.47% over the last month, which could indicate reduced confidence from insiders.
No recent congress trading data or AI trading signals to provide additional validation.
Amgen's Q4 2025 financials show robust growth: Revenue increased to $9.87B (up 8.58% YoY), Net Income surged to $1.33B (up 112.60% YoY), and EPS rose to 2.46 (up 112.07% YoY). Gross margin also improved to 72.88%, up 10.84% YoY, indicating strong operational efficiency.
Analyst sentiment is positive overall, with multiple firms raising price targets and maintaining Buy or Outperform ratings. UBS raised its target to $400, while RBC Capital increased it to $370. However, some firms like Morgan Stanley and Guggenheim maintain neutral ratings, citing fair valuation at current levels.
